ESR1 and breast cancer: MCF-7 xenograft in the tamoxifen + anordrin (TAM + ANO) group exhibited similar mass to those mice in the TAM group (Fig. 3g, TAM (green bar) vs. TAM + ANO (blue bar)), suggesting that anordrin did not affect the tamoxifen activity of ER+ breast cancer resistance in vivo.